Skip to main content

Table 1 Baseline characteristics

From: Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables

Characteristic

Male

Female

All

 

Mean±SD

Age, yrs

58.39±12.01

59.09±11.32

58.72±11.69

BMI, kg/m2

24.47±2.92

24.38±3.41

24.43±3.16

Duration of diabetes, yr

5.43±5.16

5.71±5.40

5.57±5.28

HbA1c, %

7.90±1.73

7.80±1.71

7.85±1.72

FPG, mmol/L

8.12±2.40

8.02±2.39

8.07±2.39

2hPPG, mmol/L

11.26±3.64

11.12±3.63

11.19±3.64

SBP, mmHg

132.35±14.79

131.39±15.50

131.89±15.14

DBP, mmHg

81.86±11.00

80.10±11.05

81.02±11.06

Triglycerides, mmol/L

2.22±1.65

2.10±1.46

2.16±1.56

Total cholesterol, mmol/L

4.71±1.48

4.75±1.48

4.73±1.48

LDL, mmol/L

2.92±1.16

2.92±1.16

2.92±1.16

Reason for insulin initiation, n (%)

   

OAD ineffective

33341 (77.18)

29525 (78.17)

62866 (77.64)

Complication

5531 (12.80)

4862 (12.87)

10393 (12.84)

Patient requests

3041 (7.04)

2382 (6.31)

5423 (6.70)

Other reason

1288 (2.98)

1003 (2.65)

2291 (2.82)

Complications and comorbidities, n (%)

   

Hypertension

41400 (33.25)

38194 (33.46)

79594 (33.35)

Coronary heart disease

12918 (10.38)

13125 (11.50)

26043 (10.91)

Dyslipidemia

25222 (20.26)

21712 (19.02)

46934 (19.67)

Cerebrovascular disease

6552 (5.26)

5526 (4.84)

12078 (5.06)

Diabetic retinopathy

9799 (7.87)

10046 (8.80)

19845 (8.32)

Diabetic neuropathy

13211 (10.61)

12930 (11.33)

26141 (10.95)

Diabetic nephropathy

7001 (5.62)

5702 (5.00)

12703 (5.32)

Diabetic foot

1380 (1.11)

1087 (0.95)

2467 (1.03)

Others

2438 (1.96)

2469 (2.16)

4907 (2.06)

  1. 2hPPG, 2-hr postprandial plasma glucose; BMI, body mass index; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; LDL, low-density lipoprotein; SBP, systolic blood pressure; SD, standard deviation.